Your browser doesn't support javascript.
loading
Improvement in severe asthma patients receiving biologics and factors associated with persistent insufficient control: a real-life national study.
Guilleminault, Laurent; Camus, Claire; Raherison-Semjen, Chantal; Capdepon, Audrey; Bourdin, Arnaud; Bonniaud, Philippe; Fry, Stéphanie; Devouassoux, Gilles; Blanc, François-Xavier; Pison, Christophe; Dupin, Clairelyne; Khayath, Naji; Courdeau, Joelle; Valcke-Brossollet, Judith; Nocent-Ejnaini, Cécilia; Rolland, Fabien; Lamandi, Carmen; Proust, Alain; Ozier, Anaig; Portel, Laurent; Gaspard, Wanda; Roux-Claude, Pauline; Beurnier, Antoine; Martinez, Stéphanie; Dot, Jean-Marc; Hennegrave, Florence; Vignal, Guillaume; Auvray, Etienne; Paleiron, Nicolas; Just, Nicolas; Miltgen, Jean; Russier, Maud; Olivier, Cécile; Taillé, Camille; Didier, Alain.
Affiliation
  • Guilleminault L; Department of Respiratory Medicine, Faculty of Medicine, Toulouse University Hospital Centre, 24 chemin de Pouvourville, Toulouse 31059, France.
  • Camus C; Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), Inserm U1291, University of Toulouse, CNRS U5282, Toulouse, France.
  • Raherison-Semjen C; CRISALIS/F-CRIN INSERM Network, Toulouse, France.
  • Capdepon A; CRISALIS/F-CRIN INSERM Network, Toulouse, France.
  • Bourdin A; CRISALIS/F-CRIN INSERM Network, Toulouse, France.
  • Bonniaud P; University of French West Indies, Respiratory Diseases Department, Pointe -à Pitre, Guadeloupe.
  • Fry S; AstraZeneca, Paris, France.
  • Devouassoux G; CRISALIS/F-CRIN INSERM Network, Toulouse, France.
  • Blanc FX; Respiratory Diseases Department, Montpellier University Hospital, Montpellier, France.
  • Pison C; CRISALIS/F-CRIN INSERM Network, Toulouse, France.
  • Dupin C; Respiratory Diseases Department, Dijon University Hospital, Dijon, France.
  • Khayath N; CRISALIS/F-CRIN INSERM Network, Toulouse, France.
  • Courdeau J; Respiratory Diseases Department, Lille University Hospital, Lille, France.
  • Valcke-Brossollet J; CRISALIS/F-CRIN INSERM Network, Toulouse, France.
  • Nocent-Ejnaini C; Respiratory Diseases Department, Lyon University Hospital, HCL, Lyon, France.
  • Rolland F; CRISALIS/F-CRIN INSERM Network, Toulouse, France.
  • Lamandi C; Nantes Université, CHU de Nantes, INSERM, Service de Pneumologie, CIC 1413, l'Institut du Thorax, Nantes, France.
  • Proust A; CRISALIS/F-CRIN INSERM Network, Toulouse, France.
  • Ozier A; Respiratory Diseases Department, Grenoble University Hospital, Grenoble, France.
  • Portel L; CRISALIS/F-CRIN INSERM Network, Toulouse, France.
  • Gaspard W; Respiratory Diseases Department, Bichat Hospital, AP-HP, Paris, France.
  • Roux-Claude P; CRISALIS/F-CRIN INSERM Network, Toulouse, France.
  • Beurnier A; Respiratory Diseases Department, Strasbourg University Hospital, Strasbourg, France.
  • Martinez S; Respiratory Diseases Department, Bigorre Hospital, Tarbes, France.
  • Dot JM; Private practice in Armand Brillard Hospital, Nogent-sur-Marne, France.
  • Hennegrave F; Respiratory Diseases Department, Côte-Basque Hospital, Bayonne, France.
  • Vignal G; Respiratory Diseases Department, Cannes Hospital, Cannes, France.
  • Auvray E; Respiratory Diseases Department, GHRMSA Hospital, Mulhouse, France.
  • Paleiron N; Respiratory Diseases Department, Nimes Hospital, Nîmes, France.
  • Just N; Respiratory Diseases Department, Saint Augustin Clinic, Bordeaux, France.
  • Miltgen J; Respiratory Diseases Department, Libourne Hospital, Libourne, France.
  • Russier M; Respiratory Diseases Department, Army Training Hospital HIA Percy Clamart, Clamart, France.
  • Olivier C; CRISALIS/F-CRIN INSERM Network, Toulouse, France.
  • Taillé C; Respiratory Diseases Department, Jean Minjoz University Hospital, Besançon, France.
  • Didier A; CRISALIS/F-CRIN INSERM Network, Toulouse, France.
Ther Adv Respir Dis ; 17: 17534666231202749, 2023.
Article in En | MEDLINE | ID: mdl-37966015
ABSTRACT

BACKGROUND:

Biological therapies have revolutionized the treatment of severe asthma with type 2 inflammation. Although such treatments are very effective in reducing exacerbation and the dose of oral steroids, little is known about the persistence of symptoms in severe asthma patients treated with biologics.

PURPOSE:

We aim to describe asthma control and healthcare consumption of severe asthma patients treated with biologics.

DESIGN:

The Second Souffle study is a real-life prospective observational study endorsed by the Clinical Research Initiative in Severe Asthma a Lever for Innovation & Science Network.

METHODS:

Adults with a confirmed diagnosis of severe asthma for at least 12 months' duration were enrolled in the study. A self-administered questionnaire including the Asthma Control Questionnaire (ACQ), Asthma Quality of Life Questionnaire (AQLQ) and a compliance evaluation test was given to the patients. Healthcare consumption within 12 months prior to enrolment was documented. In patients receiving biologics, doctors indicated whether the patients were biologic responders or non-responders.

RESULTS:

The characteristics of 431 patients with severe asthma were analysed. Among them, 409 patients (94.9%) presented asthma with type 2 inflammation (T2 high) profile, and 297 (72.6%) patients with a T2 high phenotype were treated with a biologic. Physicians estimated that 88.2% of patients receiving biologics were responders. However, asthma control was only achieved in 25.3% of those patients (ACQ > 0.75). A high proportion of patients (77.8%) identified as responders to biologics were not controlled according to the ACQ score. About 50% of patients continue to use oral corticosteroids either daily (25.2%) or more than three times a year for at least three consecutive days (25.6%). Gastro-oesophageal Reflux Disease (GERD) and Obstructive Sleep Apnoea syndrome (OSA) were identified as independent factors associated with uncontrolled asthma.

CONCLUSION:

Although a high proportion of severe asthma patients respond to biologics, only 25.3% have controlled asthma. GERD and OSA are independent factors of uncontrolled asthma.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Asthma / Biological Products / Gastroesophageal Reflux / Anti-Asthmatic Agents / Sleep Apnea, Obstructive Limits: Adult / Humans Language: En Journal: Ther Adv Respir Dis Journal subject: PNEUMOLOGIA / TERAPEUTICA Year: 2023 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Asthma / Biological Products / Gastroesophageal Reflux / Anti-Asthmatic Agents / Sleep Apnea, Obstructive Limits: Adult / Humans Language: En Journal: Ther Adv Respir Dis Journal subject: PNEUMOLOGIA / TERAPEUTICA Year: 2023 Document type: Article Affiliation country: